Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

The research on the immune microenvironment of patients with relapse or refractory diffuse large b faced drug resistance to CD20/CD3 bispecific antibodies

Shujuan Wen, Shan Li, Yiwei Zhou, Mei Wu, Yong Sun, Lin Zhu, Xin Hu, Li Guo, Hui Zhou

Blood (2025) 146 (Supplement 1): 7073.

https://doi.org/10.1182/blood-2025-7073

Published: 2025

Journal Articles

Inequity in travel burden among patients receiving bispecific antibodies (BsAbs) for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): A real-world study of Medicare beneficiaries in the United States (US)

Zachary Frosch, Anthony Masaquel, Esprit Ma, Eric Zuk, Matthew Davis, Fadoua El Moustaid, Mei Wu, Carolina Reyes, Lourenia Cassoli, Scott Huntington

Blood (2025) 146 (Supplement 1): 2622.

https://doi.org/10.1182/blood-2025-2622

Published: 2025

Journal Articles

Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study

John M. Burke, Jeff Sharman, Bertrand Anz, Richard Zuniga, Aung Tun, David Wright, Prachi Jani, Juliana Biondo, Mei Wu, Yong Mun, Vivek S. Chopra, Rona Farighi, Jose Villasboas Bisneto, Elizabeth Budde, Ian Flinn

Blood (2025) 146 (Supplement 1): 228.

https://doi.org/10.1182/blood-2025-228

Published: 2025

Journal Articles

Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma

Jose Villasboas Bisneto, John M. Burke, Aung Tun, Steve Liu, Jeff Sharman, Juliana Biondo, Prachi Jani, Mei Wu, Yong Mun, Vivek S. Chopra, Rona Farighi, Javier Munoz, Furhan Yunus, Ian Flinn, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2025-1807

Published: 2025

Journal Articles

Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study

Jeff Sharman, Aung Tun, Jose Villasboas Bisneto, Ayed Ayed, Prachi Jani, Juliana Biondo, Mei Wu, Farah Hossain, Yong Mun, Vivek S. Chopra, Rona Farighi, Jamal Misleh, Shachar Peles, Ian Flinn, John M. Burke

Blood (2025) 146 (Supplement 1): 62.

https://doi.org/10.1182/blood-2025-62

Published: 2025

Journal Articles

Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Adam Braun, Nancy Bartlett, Dai Chihara, Loretta Nastoupil, Mazyar Shadman, Dimitrios Tzachanis, Hunter Cochran, Jennifer Huang, Mei Wu, Michael C. Wei, Shen Yin, Jing Qi Hao, Qian Zhu, Yong Mun, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 6261.

https://doi.org/10.1182/blood-2025-6261

Published: 2025

Journal Articles

Differences in patient-reported time toxicity between bispecific antibody (BsAb) options: Impact of treatment duration and dosing frequency on patient-reported time burden in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

Ajay Major, Esprit Ma, Anthony Masaquel, Mazie Tsang, Mengyang Di, Supreet Kaur, Priyanka Pophali, Sally Werner, Rebecca Bungay, Dominick Latremouille-Viau, Annie Guerin, Carolina Reyes, Mei Wu, Lourenia Cassoli, Pallawi Torka

Blood (2025) 146 (Supplement 1): 6181.

https://doi.org/10.1182/blood-2025-6181

Published: 2025

Journal Articles

Diverse preferences for treatment options in relapsed/refractory (R/R) follicular lymphoma (FL): Survey results from patients in the United States (US)

Krish Patel, Esprit Ma, Mei Wu, Kelley Myers, Cooper Bussberg, Jayne Galinsky, Zachary Frosch

Blood (2025) 146 (Supplement 1): 6180.

https://doi.org/10.1182/blood-2025-6180

Published: 2025

Journal Articles

Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States

Matthew Matasar, Katherine L Rosettie, Almut Mecke, Danilo Di Maio, Shih-Wen Lin, Mei Wu, Esprit Ma

Blood (2024) 144 (Supplement 1): 3648.

https://doi.org/10.1182/blood-2024-198657

Published: 2024

Journal Articles

Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study

John M. Burke, Ian W. Flinn, L. Elizabeth Budde, Aung M. Tun, Steven Liu, Juliana M.L. Biondo, Prachi Jani, Mei Wu, Yong Mun, Vivek S. Chopra, Jessica M. Grindheim, Dana Farinella, Jose C. Villasboas Bisneto

Blood (2024) 144 (Supplement 1): 3008.

https://doi.org/10.1182/blood-2024-194604

Published: 2024

Journal Articles

Efficacy and Safety Outcomes of CAR T-Cell Therapies in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Who Received Prior Treatment with Mosunetuzumab

Adam Braun, Stephen J. Schuster, Loretta Nastoupil, Nancy L. Bartlett, Mazyar Shadman, Anita Kumar, Dimitrios Tzachanis, Dai Chihara, Mei Wu, Michael C. Wei, Shen Yin, Jing Qi Hao, Qian Zhu, Yong Mun, L. Elizabeth Budde

Blood (2024) 144 (Supplement 1): 6555.

https://doi.org/10.1182/blood-2024-198409

Published: 2024

Journal Articles

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Scott F Huntington, Anthony Masaquel, Esprit Ma, Eric Zuk, Hélène Parisé, Matthew Davis, David Fox, Fadoua El Moustaid, Arliene Mangalindan, Lourenia Cassoli, Mei Wu, Zachary AK Frosch

Blood (2024) 144 (Supplement 1): 782.

https://doi.org/10.1182/blood-2024-198414

Published: 2024

Journal Articles

Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective

Matthew Matasar, Katherine L Rosettie, Shih-Wen Lin, Mei Wu, Esprit Ma

Blood (2024) 144 (Supplement 1): 5029.

https://doi.org/10.1182/blood-2024-198660

Published: 2024

Journal Articles

Anti-PD-1 Antibody (Tislelizumab) Combined with R-CHOP for the Treatment of Previously Untreated Primary Mediastinal B-Cell Lymphoma: A Prospective Phase II Study

Mei Wu, Lin Zhu, Shan Li, Tuerde Jiaerbao, Shanshan Wang, Xiao Liang, Xin Hu, Li Guo, Abulikemujiang Adili, Xianmusiya Maimaitirexiati, Ruirui Ren, Zhihua Yao, Shuna Yao, Shujuan Wen

Blood (2023) 142 (Supplement 1): 6236.

https://doi.org/10.1182/blood-2023-182504

Published: 2023

Journal Articles

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

Elise A. Chong, Elicia Penuel, Nancy L. Bartlett, Francesc Bosch, L. Elizabeth Budde, Keith Fay, Ian W. Flinn, Andre Goy, Anita Kumar, Rachel Lundberg, Ellen B. Napier, Loretta J. Nastoupil, Mazyar Shadman, Michael C. Wei, Mei Wu, Shen Yin, Emeline R. Chong, Stephen J. Schuster

Blood (2023) 142 (Supplement 1): 1752.

https://doi.org/10.1182/blood-2023-190201

Published: 2023

Journal Articles

Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study

Ian W. Flinn, L. Elizabeth Budde, Aung M. Tun, John M. Burke, Bertrand Anz, Shachar Peles, Jeff P. Sharman, Praveen K. Tumula, Juliana M. L. Biondo, Prachi Jani, Mei Wu, Tony Lin, Neha Parmar, Yong Mun, Nai-Shun Yao, Steven Liu

Blood (2023) 142 (Supplement 1): 3029.

https://doi.org/10.1182/blood-2023-177917

Published: 2023

Journal Articles

Treatment Patterns and Outcomes Among Patients with Relapsed/Refractory Follicular Lymphoma Treated in Routine Clinical Practice in the US with Three or More Lines of Therapy

Jamie T. Ta, Stella Arndorfer, Cristina Julian, Mei Wu, Dominic Lai, Sheila Shapouri

Blood (2021) 138 (Supplement 1): 4080.

https://doi.org/10.1182/blood-2021-145412

Published: 2021

Journal Articles

Healthcare Resource Utilization and Costs of Patients with Relapsed/Refractory Follicular Lymphoma Receiving 3 or More Lines of Therapy

Matthew J. Matasar, Sheila Shapouri, Jamie T. Ta, Tu My To, Mei Wu, Rongrong Wang

Blood (2021) 138 (Supplement 1): 1923.

https://doi.org/10.1182/blood-2021-145407

Published: 2021

Journal Articles

Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

Hsu-Chih Chien, PhD MSc, Vikas Patil, MS, Kelli M Rasmussen, MS, Christina Yong, MA, Juliana M L Biondo, MD, Mary Halloran, PharmD, BCPS, Sheila Shapouri, PharmD, MS, Mei Wu, PharmD, Zachary R Burningham, PhD, Brian C Sauer, PhD, Ahmad S Halwani, MD

Blood (2019) 134 (Supplement_1): 4309.

https://doi.org/10.1182/blood-2019-128645

Published: 2019

Journal Articles

c-Myb acts in parallel and cooperatively with Cebp1 to regulate neutrophil maturation in zebrafish

Hao Jin, Zhibin Huang, Yali Chi, Mei Wu, Riyang Zhou, Lingfeng Zhao, Jin Xu, Fenghua Zhen, Yahui Lan, Li Li, Wenqing Zhang, Zilong Wen, Yiyue Zhang

Blood (2016) 128 (3): 415–426.

https://doi.org/10.1182/blood-2015-12-686147

Published: 2016

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The research on the immune microenvironment of patients with relapse or refractory diffuse large b faced drug resistance to CD20/CD3 bispecific antibodies

Inequity in travel burden among patients receiving bispecific antibodies (BsAbs) for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): A real-world study of Medicare beneficiaries in the United States (US)

Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study

Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma

Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study

Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Differences in patient-reported time toxicity between bispecific antibody (BsAb) options: Impact of treatment duration and dosing frequency on patient-reported time burden in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

Diverse preferences for treatment options in relapsed/refractory (R/R) follicular lymphoma (FL): Survey results from patients in the United States (US)

Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States

Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study

Efficacy and Safety Outcomes of CAR T-Cell Therapies in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Who Received Prior Treatment with Mosunetuzumab

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective

Anti-PD-1 Antibody (Tislelizumab) Combined with R-CHOP for the Treatment of Previously Untreated Primary Mediastinal B-Cell Lymphoma: A Prospective Phase II Study

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study

Treatment Patterns and Outcomes Among Patients with Relapsed/Refractory Follicular Lymphoma Treated in Routine Clinical Practice in the US with Three or More Lines of Therapy

Healthcare Resource Utilization and Costs of Patients with Relapsed/Refractory Follicular Lymphoma Receiving 3 or More Lines of Therapy

Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

c-Myb acts in parallel and cooperatively with Cebp1 to regulate neutrophil maturation in zebrafish

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only